Clinical trials
Rosai Dorfman Disease clinical trials
Below are recruiting rosai dorfman disease clinical trials, each written for real people, not researchers. We’re tracking 7 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04079179RecruitingPhase 2
Cobimetinib for difficult Langerhans cell and similar disorders
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
Phoenix, ArizonaAges Any age - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05915208Recruiting
Follow-up study for people with histiocytic disorders
This study is checking in over time with people who have a histiocytic disorder. It may help doctors better understand how these conditions behave and what follow-up care works best.
Birmingham, AlabamaAges birth–89 years - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07187167RecruitingPhase 2
Lenalidomide and dexamethasone for Rosai-Dorfman disease
This trial tests a combination of two drugs, lenalidomide and dexamethasone (called the RD regimen), for people with Rosai-Dorfman disease, a rare disorder that causes immune cells to build up in the body. Researchers want to see if this treatment is safe and effective for patients who are newly diagnosed or whose disease has come back or not improved with other treatments.
BeijingAges 18–80 - NCT02285582Recruiting
Rare blood disorder registry for histiocytic conditions
This study is a registry that collects information about people diagnosed with rare histiocytic disorders. It helps doctors better understand these conditions over time and may improve future care.
Birmingham, AlabamaAges Any age - NCT06153173RecruitingPhase 2
Mirdametinib for histiocytic disorders
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
Cincinnati, OhioAges 2 years+
Hear when a new Rosai Dorfman Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rosai dorfman disease?
- Yes. Clin2 currently lists 7 recruiting rosai dorfman disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rosai dorfman disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rosai dorfman disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.